Bosh sahifa207940 ā¢ KRX
add
Samsung Biologics Co Ltd
Yopilish kursi
1Ā 052Ā 000,00Ā ā©
Kunlik diapazon
1Ā 042Ā 000,00Ā ā© - 1Ā 086Ā 000,00Ā ā©
Yillik diapazon
721Ā 000,00Ā ā© - 1Ā 209Ā 000,00Ā ā©
Bozor kapitalizatsiyasi
77,22Ā trln KRW
OŹ»rtacha hajm
71,72Ā ming
Narx/foyda
71,28
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (KRW) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,26Ā trln | 17,04% |
Joriy xarajat | 334,17Ā mlrd | 87,16% |
Sof foyda | 321,49Ā mlrd | 10,60% |
Sof foyda marjasi | 25,59 | -5,50% |
Har bir ulushga tushum | 4,52Ā ming | 10,60% |
EBITDA | 476,48Ā mlrd | -3,14% |
Amaldagi soliq stavkasi | 14,04% | ā |
Balans
Jami aktivlari
Jami passivlari
| (KRW) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,33Ā trln | -35,26% |
Jami aktivlari | 17,34Ā trln | 8,04% |
Jami passivlari | 6,43Ā trln | 3,47% |
Umumiy kapital | 10,90Ā trln | ā |
Tarqatilgan aksiyalar | 71,17Ā mln | ā |
Narxi/balansdagi bahosi | 6,87 | ā |
Aktivlardan daromad | 4,88% | ā |
Kapitaldan daromad | 6,80% | ā |
Pul aylanmasi
Naqd pulning sof oŹ»zgarishi
| (KRW) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 321,49Ā mlrd | 10,60% |
Operatsiyalardan naqd pul | 389,56Ā mlrd | -53,23% |
Sarmoyadan naqd pul | -1,07Ā trln | -138,92% |
Moliyadan naqd pul | 514,35Ā mlrd | 280,15% |
Naqd pulning sof oŹ»zgarishi | -149,00Ā mlrd | -267,89% |
BoŹ»sh pul | -30,00Ā mlrd | -107,16% |
Haqida
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Tashkil etilgan
2011
Xodimlar soni
4Ā 770
